logo
Sign In
Farxiga vs. GlyxambiBerinert vs. CinryzeEmgality vs. QuliptaFarxiga vs. InvokanaFirazyr vs. SajazirGlyxambi vs. InvokanaInvokamet vs. SynjardyOpzelura vs. DupixentOrencia vs. RinvoqQulipta vs. VyeptiStelara vs. TremfyaSynjardy vs. VictozaTaltz vs. BimzelxVyepti vs. Nurtec ODTView all Comparisons
ADHD drugsAnxiety drugsAsthma drugsAtopic dermatitis drugsDepression drugsHeart failure drugsHypertension drugsLymphoma drugsOsteoarthritis drugsRheumatoid arthritis drugsRosacea drugsSchizophrenia drugsType 2 Diabetes drugsView all Indications
Bayer drugsAbbVie drugsAstraZeneca drugsEli Lilly and Company drugsGenetech drugsGlaxoSmithKline (GSK) drugsNovartis drugsPfizer drugsTakeda Pharmaceuticals drugsTeva Pharmaceuticals drugsAmgen drugsView all Manufacturers
Beta-Adrenergic BlockerAngiotensin Converting Enzyme InhibitorAngiotensin 2 Receptor BlockerCalcium Channel BlockerDiureticsHMG-CoA Reductase InhibitorProton Pump InhibitorSelective Serotonin Reuptake InhibitorNorepinephrine Reuptake InhibitorBenzodiazepinesOpioid AgonistsNonsteroidal Anti-inflammatory DrugsAntiepileptic AgentsAntipsychoticsAntihistaminesView all Classes
Wegovy®Ozempic®Mounjaro®Zepbound®Jardiance®Farxiga®Dupixent®Trulicity®Lyrica®Lipitor®Effexor®Concerta®Depakote®Trintellix®Rexulti®Rinvoq®Verzenio®Taltz®
For ProvidersRequest DemoJoin Research Panel
For BusinessHCP ChannelCommercial O/SEngageMarketplaceOneHubInsight
Tools & MorePrescribing InfoCoverageSavingsPatient ResourcesA-Z IndicationsCompare Drugs
CompanyAboutInsightsCareersContactSecurity
Legit Script Certified
Get the latest insights in your inbox
Follow us
Legit Script Certified
  • Terms and Conditions
  • Privacy Policy
  • © 2025 PrescriberPoint. All Rights Reserved.

    • Microtubule Inhibitor class drugs

    FiltersReset Filters
    7 results

    • abraxane

      (Paclitaxel)
      Abraxis BioScience, LLC
      Usage: ABRAXANE is indicated for treating metastatic breast cancer after chemotherapy failure, as well as for first-line treatment of locally advanced or metastatic non-small cell lung cancer in combination with carboplatin. It is also indicated for first-line treatment of metastatic pancreatic adenocarcinoma combined with gemcitabine.

    • halaven

      (eribulin mesylate)
      BSP Pharmaceuticals SpA

    • halaven

      (eribulin mesylate)
      Eisai Inc.
      Usage: HALAVEN is indicated for treating metastatic breast cancer in patients who have received at least two prior chemotherapy regimens, including anthracyclines and taxanes, and for unresectable or metastatic liposarcoma in patients previously treated with an anthracycline-containing regimen.

    • ixempra

      (ixabepilone)
      R-Pharm US Operating, LLC
      Usage: IXEMPRA is indicated for treating patients with metastatic or locally advanced breast cancer that is resistant to anthracyclines and taxanes, or when further anthracycline therapy is contraindicated. It can be used in combination with capecitabine or as a single agent when tumors are resistant to multiple treatments.

    • jevtana

      (cabazitaxel)
      Sanofi-Aventis U.S. LLC
      Usage: JEVTANA® is indicated for use with prednisone in treating patients with metastatic castration-resistant prostate cancer who have previously undergone treatment with a docetaxel-containing regimen.

    • klisyri

      (tirbanibulin)
      Almirall, LLC
      Usage: KLISYRI is indicated for the topical treatment of actinic keratosis specifically on the face or scalp.

    • paclitaxel

      (Paclitaxel)
      Teva Pharmaceuticals, Inc.
      Usage: Paclitaxel Protein-Bound Particles for Injectable Suspension is indicated for treating metastatic breast cancer post-chemotherapy failure, first-line therapy for non-small cell lung cancer in combination with carboplatin, and first-line treatment of metastatic adenocarcinoma of the pancreas with gemcitabine.